Allergy Therapeutics (Allergy Therapeutics) Debt-to-Equity

: 0.37 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.22 Mil. Allergy Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.25 Mil. Allergy Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $33.50 Mil. Allergy Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.37.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Allergy Therapeutics's Debt-to-Equity or its related term are showing as below:

AGYTF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.12 Max: 17.42
Current: 0.37

During the past 13 years, the highest Debt-to-Equity Ratio of Allergy Therapeutics was 17.42. The lowest was 0.00. And the median was 0.12.

AGYTF's Debt-to-Equity is ranked worse than
57.19% of 855 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs AGYTF: 0.37

Allergy Therapeutics Debt-to-Equity Historical Data

The historical data trend for Allergy Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

0.07

0.28

0.23

0.28

17.42

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity																0.18	0.28	0.26	17.42	0.37

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Debt-to-Equity falls into.

Allergy Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Allergy Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.277	+	43.164)	/	2.609
	=	17.42

Allergy Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.215	+	10.253)	/	33.496
	=	0.37

Allergy Therapeutics (OTCPK:AGYTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Allergy Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (Allergy Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AGY:UK HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.